The meta-genome of sepsis: Host genetics, pathogens and the acute immune response

Journal of Innate Immunity

Volumn 6, Issue 3, 2014, Pages 272-283

  Boyd, John H ^a   Russell, James A ^a   Fjell, Chris D ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Gene expression; Genetics; Meta genome; Microbiome; Sepsis

Indexed keywords

ALPHA2 INTERFERON; CD135 ANTIGEN; CXCL1 CHEMOKINE; EOTAXIN; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; FRACTALKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; INTERLEUKIN 9; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3;

ANTIBIOTIC THERAPY; BACTERIAL LOAD; CD4+ T LYMPHOCYTE; COMMUNITY ACQUIRED PNEUMONIA; GENE EXPRESSION; GENETIC VARIABILITY; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE RESPONSE; IMMUNE STATUS; INFECTION RISK; INFLAMMATION; METAGENOME; MICROBIAL DIVERSITY; MICROBIOME; MICROORGANISM DETECTION; MOLECULAR DIAGNOSTICS; MORTALITY; MULTIPLEX POLYMERASE CHAIN REACTION; NONHUMAN; PATHOGEN LOAD; PRIORITY JOURNAL; REVIEW; RNA SEQUENCE; SEPSIS; SEPTIC SHOCK; SURVIVAL RATE; BACTERIAL GROWTH; BLOOD; CLINICAL FEATURE; DENSITY; HOST; HOST RESISTANCE; ACUTE DISEASE; BACTERIAL INFECTIONS; BIODIVERSITY; GENETIC PREDISPOSITION; GENETICS; HIGH THROUGHPUT SCREENING; IMMUNITY; IMMUNOLOGY; MICROFLORA; MOLECULAR PATHOLOGY;

ACUTE DISEASE; BACTERIAL INFECTIONS; BIODIVERSITY; GENETIC PREDISPOSITION TO DISEASE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; IMMUNITY; METAGENOME; MICROBIOTA; PATHOLOGY, MOLECULAR; SEPSIS;

EID: 84893649138     PISSN: 1662811X     EISSN: 16628128     Source Type: Journal    
DOI: 10.1159/000358835     Document Type: Review

References (65)

1. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb SA, Beale RJ, Vincent JL, Moreno R: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41: 580-637.
2. Russell JA: Management of sepsis. N Engl J Med 2006; 355: 1699-1713.
3. Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy DM, Pinsky MR, Fine J, Krichevsky A, Delude RL, Angus DC: Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) study. Arch Intern Med 2007; 167: 1655-1663.
4. Fjell CD, Thair S, Hsu JL, Walley KR, Russell JA, Boyd J: Cytokines and signaling molecules predict clinical outcomes in sepsis. PLoS One 2013; 8:e79207.
5. Russell JA, Fjell C, Hsu JL, Lee T, Boyd J, Thair S, Singer J, Patterson AJ, Walley KR: Vasopressin compared with norepinephrine augments the decline of plasma cytokine levels in septic shock. Am J Respir Crit Care Med 2013; 188: 356-364.
6. Hotchkiss RS, Tinsley KW, Swanson PE, Schmieg RE Jr, Hui JJ, Chang KC, Osborne DF, Freeman BD, Cobb JP, Buchman TG, Karl IE: Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol 2001; 166: 6952-6963.
7. Venet F, Chung CS, Kherouf H, Geeraert A, Malcus C, Poitevin F, Bohe J, Lepape A, Ayala A, Monneret G: Increased circulating regulatory T cells (CD4+CD25 +CD127-) contribute to lymphocyte anergy in septic shock patients. Intensive Care Med 2009; 35: 678-686.
8. Alejandria MM, Lansang MA, Dans LF, Mantaring JB: Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database Syst Rev 2002;CD001090.
9. Werdan K, Pilz G, Bujdoso O, Fraunberger P, Neeser G, Schmieder RE, Viell B, Marget W, Seewald M, Walger P, Stuttmann R, Speichermann N, Peckelsen C, Kurowski V, Osterhues HH, Verner L, Neumann R, Muller-Werdan U: Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study. Crit Care Med 2007; 35: 2693-2701.
10. Brun-Buisson C, Doyon F, Carlet J, Dellamonica P, Gouin F, Lepoutre A, Mercier JC, Offenstadt G, Regnier B: Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU group for severe sepsis. JAMA 1995; 274: 968-974.
11. Wang HE, Shapiro NI, Angus DC, Yealy DM: National estimates of severe sepsis in United States emergency departments. Crit Care Med 2007; 35: 1928-1936.
12. McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR: Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS trial study group. Ann Intern Med 1994; 121: 1-5.
13. Angus DC, Birmingham MC, Balk RA, Scannon PJ, Collins D, Kruse JA, Graham DR, Dedhia HV, Homann S, MacIntyre N: E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators. JAMA 2000; 283: 1723-1730.
14. Albertson TE, Panacek EA, MacArthur RD, Johnson SB, Benjamin E, Matuschak GM, Zaloga G, Maki D, Silverstein J, Tobias JK, Haenftling K, Black G, Cowens JW: Multicenter evaluation of a human monoclonal antibody to enterobacteriaceae common antigen in patients with Gram-negative sepsis. Crit Care Med 2003; 31: 419-427.
15. Abraham E, Glauser MP, Butler T, Garbino J, Gelmont D, Laterre PF, Kudsk K, Bruining HA, Otto C, Tobin E, Zwingelstein C, Lesslauer W, Leighton A: P55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. JAMA 1997; 277: 1531-1538.
16. Abraham E, Laterre PF, Garbino J, Pingleton S, Butler T, Dugernier T, Margolis B, Kudsk K, Zimmerli W, Anderson P, Reynaert M, Lew D, Lesslauer W, Passe S, Cooper P, Burdeska A, Modi M, Leighton A, Salgo M, Van der Auwera P: Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Crit Care Med 2001; 29: 503-510.
17. Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, Bone R, Wenzel RP, Balk R, Allred R, et al: Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, doubleblind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 1995; 273: 934-941.
18. Cohen J, Carlet J: INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 1996; 24: 1431-1440.
19. Panacek EA, Marshall JC, Albertson TE, Johnson DH, Johnson S, MacArthur RD, Miller M, Barchuk WT, Fischkoff S, Kaul M, Teoh L, Van Meter L, Daum L, Lemeshow S, Hicklin G, Doig C: Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab ? )2 fragment afelimomab in patients with severe sepsis and elevated interleukin- 6 levels. Crit Care Med 2004; 32: 2173-2182.
20. Sprung CL, Caralis PV, Marcial EH, Pierce M, Gelbard MA, Long WM, Duncan RC, Tendler MD, Karpf M: The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. N Engl J Med 1984; 311: 1137-1143.
21. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. The Veterans Administration Systemic Sepsis Cooperative Study Group. N Engl J Med 1987; 317: 659-665.
22. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA: A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987; 317: 653-658.
23. Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troche G, Chaumet- Riffaud P, Bellissant E: Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288: 862-871.
24. Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, Weiss YG, Benbenishty J, Kalenka A, Forst H, Laterre PF, Reinhart K, Cuthbertson BH, Payen D, Briegel J: Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008; 358: 111-124.
25. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013; 39: 165-228.
26. Russell JA, Walley KR, Singer J, Gordon AC, Hebert PC, Cooper DJ, Holmes CL, Mehta S, Granton JT, Storms MM, Cook DJ, Presneill JJ, Ayers D: Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008; 358: 877-887.
27. Kumar A, Safdar N, Kethireddy S, Chateau D: A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/meta- regression study. Crit Care Med 2010; 38: 1651-1664.
28. Kumar A: Early antimicrobial therapy in severe sepsis and septic shock. Curr Infect Dis Rep 2010; 12: 336-344.
29. Kumar A: Optimizing antimicrobial therapy in sepsis and septic shock. Crit Care Clin 2009; 25: 733-751, viii.
30. Sharma S, Kumar A: Antimicrobial management of sepsis and septic shock. Clin Chest Med 2008; 29: 677-687, ix.
31. Schloissnig S, Arumugam M, Sunagawa S, Mitreva M, Tap J, Zhu A, Waller A, Mende DR, Kultima JR, Martin J, Kota K, Sunyaev SR, Weinstock GM, Bork P: Genomic variation landscape of the human gut microbiome. Nature 2013; 493: 45-50.
32. Yatsunenko T, Rey FE, Manary MJ, Trehan I, Dominguez-Bello MG, Contreras M, Magris M, Hidalgo G, Baldassano RN, Anokhin AP, Heath AC, Warner B, Reeder J, Kuczynski J, Caporaso JG, Lozupone CA, Lauber C, Clemente JC, Knights D, Knight R, Gordon JI: Human gut microbiome viewed across age and geography. Nature 2012; 486: 222-227.
33. Gravitz L: Microbiome: the critters within. Nature 2012; 485:S12-S13.
34. Sutherland AM, Walley KR, Russell JA: Polymorphisms in CD14, mannose-binding lectin, and Toll-like receptor-2 are associated with increased prevalence of infection in critically ill adults. Crit Care Med 2005; 33: 638-644.
35. Nakada TA, Russell JA, Boyd JH, Walley KR: Il17a genetic variation is associated with altered susceptibility to gram-positive infection and mortality of severe sepsis. Crit Care 2011; 15:R254.
36. Sutherland AM, Walley KR, Nakada TA, Sham AH, Wurfel MM, Russell JA: A nonsynonymous polymorphism of IRAK4 associated with increased prevalence of Gram-positive infection and decreased response to Toll-like receptor ligands. J Innate Immun 2011; 3: 447-458.
37. Dale AP, Read RC: Genetic susceptibility to meningococcal infection. Expert Rev Anti Infect Ther 2013; 11: 187-199.
38. Pontillo A, Carvalho MS, Kamada AJ, Moura R, Schindler HC, Duarte AJ, Crovella S: Susceptibility to mycobacterium tuberculosis infection in HIV-positive patients is associated with CARD8 genetic variant. J Acquir Immune Defic Syndr 2013; 63: 147-151.
39. Sutherland AM, Walley KR, Manocha S, Russell JA: The association of interleukin 6 haplotype clades with mortality in critically ill adults. Arch Intern Med 2005; 165: 75-82.
40. Walley KR, Russell JA: Protein c-1641 AA is associated with decreased survival and more organ dysfunction in severe sepsis. Crit Care Med 2007; 35: 12-17.
41. Russell JA, Wellman H, Walley KR: Protein C rs2069912 C allele is associated with increased mortality from severe sepsis in North Americans of East Asian ancestry. Hum Genet 2008; 123: 661-663.
42. Thair SA, Walley KR, Nakada TA, McConechy MK, Boyd JH, Wellman H, Russell JA: A single nucleotide polymorphism in NFkappaB inducing kinase is associated with mortality in septic shock. J Immunol 2011; 186: 2321-2328.
43. Wacharasint P, Nakada TA, Boyd JH, Russell JA, Walley KR: AA genotype of IL-8 -251A/T is associated with low PaO(2)/FiO(2) in critically ill patients and with increased IL-8 expression. Respirology 2012; 17: 1253-1260.
44. Nakada TA, Russell JA, Boyd JH, Aguirre- Hernandez R, Thain KR, Thair SA, Nakada E, McConechy M, Walley KR: Beta2-adrenergic receptor gene polymorphism is associated with mortality in septic shock. Am J Respir Crit Care Med 2010; 181: 143-149.
45. Nakada TA, Russell JA, Wellman H, Boyd JH, Nakada E, Thain KR, Thair SA, Hirasawa H, Oda S, Walley KR: Leucyl/cystinyl aminopeptidase gene variants in septic shock. Chest 2011; 139: 1042-1049.
46. Nakada TA, Russell JA, Boyd JH, McLaughlin L, Nakada E, Thair SA, Hirasawa H, Oda S, Walley KR: Association of angiotensin II type 1 receptor-associated protein gene polymorphism with increased mortality in septic shock. Crit Care Med 2011; 39: 1641-1648.
47. Reinhart K, Bauer M, Riedemann NC, Hartog CS: New approaches to sepsis: molecular diagnostics and biomarkers. Clin Microbiol Rev 2012; 25: 609-634.
48. Paolucci M, Landini MP, Sambri V: Conventional and molecular techniques for the early diagnosis of bacteraemia. Int J Antimicrob Agents 2010; 36(suppl 2):S6-S16.
49. Kim DM, Jung SI, Jang HC, Lee CS, Lee SH, Yun NR, Neupane GP, Park KH: Vibrio vulnificus DNA load and mortality. J Clin Microbiol 2011; 49: 413-415.
50. Ho YC, Chang SC, Lin SR, Wang WK: High levels of mecA DNA detected by a quantitative real-time PCR assay are associated with mortality in patients with methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2009; 47: 1443-1451.
51. Hackett SJ, Guiver M, Marsh J, Sills JA, Thomson AP, Kaczmarski EB, Hart CA: Meningococcal bacterial DNA load at presentation correlates with disease severity. Arch Dis Childhood 2002; 86: 44-46.
52. Darton T, Guiver M, Naylor S, Jack DL, Kaczmarski EB, Borrow R, Read RC: Severity of meningococcal disease associated with genomic bacterial load. Clin Infect Dis 2009; 48: 587-594.
53. Kirkbright S, Fatovich D, Kee C, Kay I, Flexman J, Pryce TM, Waterer GW: Quantitative rt-PCR holds promise as a screening tool for patients with severe sepsis. Emerg Med Australas 2011; 23: 502-506.
54. Esparcia O, Montemayor M, Ginovart G, Pomar V, Soriano G, Pericas R, Gurgui M, Sulleiro E, Prats G, Navarro F, Coll P: Diagnostic accuracy of a 16s ribosomal DNA gene-based molecular technique (rt-PCR, microarray, and sequencing) for bacterial meningitis, early- onset neonatal sepsis, and spontaneous bacterial peritonitis. Diagn Microbiol Infect Dis 2011; 69: 153-160.
55. Pasqualini L, Mencacci A, Leli C, Montagna P, Cardaccia A, Cenci E, Montecarlo I, Pirro M, di Filippo F, Cistaro E, Schillaci G, Bistoni F, Mannarino E: Diagnostic performance of a multiple real-time PCR assay in patients with suspected sepsis hospitalized in an internal medicine ward. J Clin Microbiol 2012; 50: 1285-1288.
56. Chuang YC, Chang SC, Wang WK: Using the rate of bacterial clearance determined by realtime polymerase chain reaction as a timely surrogate marker to evaluate the appropriateness of antibiotic usage in critical patients with Acinetobacter baumannii bacteremia. Crit Care Med 2012; 40: 2273-2280.
57. Dark P, Chadwick P, Warhurst G: Detecting sepsis-associated bloodstream infection acquired in intensive care using multi-pathogen real-time PCR. J Infect 2009; 59: 296-298.
58. Dierkes C, Ehrenstein B, Siebig S, Linde HJ, Reischl U, Salzberger B: Clinical impact of a commercially available multiplex PCR system for rapid detection of pathogens in patients with presumed sepsis. BMC Infect Dis 2009; 9: 126.
59. Maubon D, Hamidfar-Roy R, Courby S, Vesin A, Maurin M, Pavese P, Ravanel N, Bulabois CE, Brion JP, Pelloux H, Timsit JF: Therapeutic impact and diagnostic performance of multiplex PCR in patients with malignancies and suspected sepsis. J Infect 2010; 61: 335-342.
60. Tran NK, Greenhalgh DG, Palmieri TL, Kost GJ: Multiplex PCR pathogen detection in two severely burned patients with suspected septicemia. J Burn Care Res 2011; 32:e172-e177.
61. Broecker F, Kube M, Klumpp J, Schuppler M, Biedermann L, Hecht J, Hombach M, Keller PM, Rogler G, Moelling K: Analysis of the intestinal microbiome of a recovered Clostridium difficile patient after fecal transplantation. Digestion 2013; 88: 243-251.
62. Neville BA, Sheridan PO, Harris HM, Coughlan S, Flint HJ, Duncan SH, Jeffery IB, Claesson MJ, Ross RP, Scott KP, O'Toole PW: Proinflammatory flagellin proteins of prevalent motile commensal bacteria are variably abundant in the intestinal microbiome of elderly humans. PLoS One 2013; 8:e68919.
63. Stringer AM, Al-Dasooqi N, Bowen JM, Tan TH, Radzuan M, Logan RM, Mayo B, Keefe DM, Gibson RJ: Biomarkers of chemotherapy- induced diarrhoea: a clinical study of intestinal microbiome alterations, inflammation and circulating matrix metalloproteinases. Support Care Cancer 2013; 21: 1843-1852.
64. Nadkarni MA, Martin FE, Jacques NA, Hunter N: Determination of bacterial load by realtime PCR using a broad-range (universal) probe and primers set. Microbiology 2002; 148: 257-266.
65. Calvano SE, Xiao W, Richards DR, Felciano RM, Baker HV, Cho RJ, Chen RO, Brownstein BH, Cobb JP, Tschoeke SK, Miller-Graziano C, Moldawer LL, Mindrinos MN, Davis RW, Tompkins RG, Lowry SF: A networkbased analysis of systemic inflammation in humans. Nature 2005; 437: 1032-1037.